DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Saxenda (liraglutide 3.0mg (daily)) costs No manufacturer cash-pay program via None — savings card discontinued June 2023, $30/month with insurance + savings card, or up to $1,349/month retail. Updated for 2026.
Same drug, different pricing channels. The spread is often $800-1000/month between cheapest and retail cash.
| Channel | Source | |
|---|---|---|
With insurance (covered, after PA) Commercial plan that covers the drug after prior authorization — copay depends on your tier. | $30/month – $200/month | Plan formulary copay tiers |
Retail / list (cash, no programs) Walk-in pharmacy price with no insurance, savings card, or manufacturer program. | $1,349/monthList price | WAC / pharmacy list, LoseLab pricing desk |
We’ll email you the day it gets cheaper — no spam, unsubscribe anytime.
Brand Saxenda retail cash-pay is $1,349.02 per month (the wholesale acquisition cost for one 30-day carton of five 3 mL prefilled pens at the 3.0 mg daily maintenance dose). Unlike Wegovy and Zepbound, Saxenda has no manufacturer direct cash-pay program — Novo Nordisk discontinued the Saxenda Savings Card on June 30, 2023 and never replaced it, steering new patients to Wegovy instead. The cheapest legitimate path in 2026 is the generic: Teva launched the first FDA-approved generic liraglutide for weight loss in August 2025, with a wholesale cost around $1,165/month and discount-card cash prices that commonly run well below the brand WAC (often in the few-hundreds-per-month range, depending on pharmacy, dose, and coupon).
If your commercial plan covers Saxenda after prior authorization, copays typically run $30–$200/month depending on tier — but Saxenda is increasingly a non-preferred or excluded agent, with many plans steering to weekly Wegovy or Zepbound first. With no active manufacturer savings card, there is no copay buy-down for the brand. The Teva generic is the better insurance play in 2026: as a true generic it lands on lower formulary tiers, and Teva's Liraglutide Injection Savings Program brings eligible commercially-insured patients to as low as $20 per prescription (commercial insurance required; uninsured and cash-pay patients are not eligible for that program).
Saxenda's cost-reduction landscape changed in 2023–2025. (1) The brand Saxenda Savings Card was discontinued June 30, 2023 — no manufacturer copay assistance exists for brand Saxenda. (2) The Novo Nordisk Patient Assistance Program provides free brand Saxenda to income-eligible uninsured patients (apply through NovoCare for current eligibility criteria). (3) Generic liraglutide (Teva, launched August 2025) is the primary affordability lever now — lower list price plus Teva's commercial-insurance savings program (as low as $20 per prescription for eligible insured patients). (4) GoodRx/SingleCare discount cards apply to the generic and can cut cash cost substantially below the brand WAC.
Medicare Part D excludes weight-loss GLP-1 prescriptions by statute, and Saxenda has no cardiovascular weight-management indication to create an exception (unlike Wegovy, whose March 2024 CV indication opened a narrow Medicare door). For Medicare members, Saxenda for weight loss is not covered in 2026 — brand or generic. The liraglutide molecule is Medicare-covered only as generic liraglutide (Victoza-equivalent) for type 2 diabetes, which is a different product and indication.
Medicaid coverage of Saxenda for adult obesity varies by state and is generally narrower than Wegovy coverage; many state formularies that cover any weight-loss GLP-1 prefer the weekly agents. The Teva generic may expand covered access on some Medicaid formularies as a lower-cost line. Check your state Medicaid formulary or our state-by-state Medicaid coverage page for verified status. Pediatric (ages 12–17) coverage is sometimes broader because Saxenda carries an on-label adolescent indication.
First FDA-approved generic GLP-1 for weight loss, launched August 2025. Same liraglutide molecule, same 3.0 mg daily dose, same daily-injection burden. WAC ~$1,165/mo; discount-card cash commonly runs in the few-hundreds-per-month range (dose-dependent), well below the brand WAC. The single biggest cost lever for staying on liraglutide.
$499/month via NovoCare direct — once-weekly, and ~15% weight loss in STEP-1 vs Saxenda's ~8% in SCALE. Nearly double the efficacy, fewer injections, and Novo actively steers Saxenda patients here.
$399–$549/month via LillyDirect — once-weekly, ~21% weight loss in SURMOUNT-1. Cheapest brand cash-pay in the category and the highest efficacy. Different molecule (dual GIP+GLP-1).
Brand Saxenda out-of-pocket ranges from ~$30/month (covered, low tier) to $1,349/month (retail cash, no programs) — and with the savings card gone since 2023, there is no manufacturer cash-pay floor for the brand. The realistic 2026 answer: if you want to stay on liraglutide, use the new Teva generic (WAC ~$1,165, with discount-card cash typically well below that); if you want more weight loss per dollar, switch to weekly Wegovy ($499 NovoCare) or Zepbound ($399–$549 LillyDirect), both of which roughly double Saxenda's efficacy. Saxenda brand is rarely the cost-optimal or efficacy-optimal choice.
Read full Saxenda review →Pricing verified monthly against current manufacturer and pharmacy formularies. Coverage rules vary by plan — verify against your member portal before prescribing.